#152088

MCF7/TAMR-4 Cell Line

Please Enter Your Email ID
Email ID

Cat. #152088

MCF7/TAMR-4 Cell Line

Cat. #: 152088

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 3-5 days

Organism: Human

Tissue: Breast

Disease: Cancer

Model: Tumour line

£800.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne Lykkesfeldt

Institute: Danish Cancer Society, Denmark

Tool Details
Target Details
Applications
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: MCF7/TAMR-4 Cell Line
  • Alternate name: MCF-7/TAMR-4 Cell Line
  • Cancer: Breast cancer
  • Cancers detailed: Breast cancer;Tamoxifen resistant
  • Research fields: Cancer;Drug development
  • Tool sub type: Continuous
  • Parental cell: MCF7 S0.5
  • Organism: Human
  • Gender: Female
  • Tissue: Breast
  • Disease: Cancer
  • Model: Tumour line
  • Conditional: Yes
  • Description: MCF7/TAMR-4 cell line is a stable tamoxifen-resistant subline. This cell line has been established in tissue culture after long term treatment with 1 uM tamoxifen. Tamoxifen (Nolvadex) is a widely used drug for hormone-dependent cancer. Tamoxifen resistance (either primary or acquired) makes oestrogen receptor-positive breast cancer much more difficult to treat. This cell line was produced from the parental cell line MCF7/S0.5, as a model cell system to study the effects of tamoxife...
  • Application: Investigate signalling pathways involved in tamoxifen resistance
  • Production details: The parental cell line for the MCF7/TAMR-4 cells is MCF7/S0.5, which was adapted to grow at low serum concentration in order to study the effect of estradiol and tamoxifen. MCF7/TAMR-4 has been established from a clone of cells that survived long term treatment with 1 uM tamoxifen. Tamoxifen-resistant cells are passaged continuously in presence of 1 uM tamoxifen, which is lethal for the parental MCF7/S0.5 cell line.
  • Biosafety level: 1
  • Additional notes: MCF7/TAMR-4 cells are oestrogen receptor positive and progesterone receptor negative. MCF7/TAMR-4 cells are growth inhibited by the pure antiestrogen fulvestrant. The oestrogen receptor is a major driver of growth of MCF7/TAMR-4 cell, ref 1. Treatment targeting the Aurora kinase A restores sensitivity to tamoxifen treatment. The TAMR lines were established from the MCF7/S0.5 cell line, which was adapted to grow with 0.5% fetal calf serum in phenol red containing DMEM/F12 medium. Treatment wi...
  • Recommended controls: MCF7-S0.5 parental line
  • Cellosaurus id: CVCL_1D42

Target Details

  • Target: Oestrogen receptor

Applications

  • Application: Investigate signalling pathways involved in tamoxifen resistance
  • Application notes: MCF7/TAMR-4 cells are oestrogen receptor positive and progesterone receptor negative. MCF7/TAMR-4 cells are growth inhibited by the pure antiestrogen fulvestrant. The oestrogen receptor is a major driver of growth of MCF7/TAMR-4 cell, ref 1. Treatment targeting the Aurora kinase A restores sensitivity to tamoxifen treatment. The TAMR lines were established from the MCF7/S0.5 cell line, which was adapted to grow with 0.5% fetal calf serum in phenol red containing DMEM/F12 medium. Treatment wi...

Handling

  • Format: Frozen
  • Passage number: Passage 402 (AL3482), 403 (AL2753)
  • Growth medium: DMEM:Ham's F-12 phenol red-free medium containing 1% fetal bovine serum, 2 mM Glutamax and 6 ng/ml insulin. To maintain high-level resistance, medium was supplemented with Tamoxifen (1 uM).
  • Temperature: 37° C
  • Atmosphere: 5% CO2
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes

Related Tools

  • Related tools: MCF7/S0.5 Cell Line

References

  • Joshi et al. 2016. Oncotarget. 7(35):57239-57253. PMID: 27528030.
  • Elias et al. 2015. Oncogene. 34(15):1919-1927. PMID: 24882577.
  • Thrane et al. 2014. Oncogene. PMID: 25362855.
  • Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470.
  • Cutrupi et al. 2012. Oncogene. 31(40):4353-4361. PMID: 22249258.
  • Millour et al. 2010. Oncogene. 29(20):2983-2995. PMID: 20208560.
  • Pancholi et al. 2008. Endocr Relat Cancer. 15(4):985-1002. PMID: 18824559.
  • Sarwar et al. 2006. Endocr R...